Davipharm

In line with Vietnam’s specific objectives for pharmaceutical industry development by 2030 and its vision toward 2045, as outlined in Decision 1165/QD-TTg of the Prime Minister, Davipharm is committed to contributing to the country’s long-term goals.

These objectives include developing Vietnam’s pharmaceutical industry to align with the standards of developed countries in the region, enhancing research capabilities, and strengthening local production of high-quality drugs. Vietnam aims to elevate its domestic pharmaceutical industry to a WHO Level 4 classification, emphasizing continuous improvement through advanced and well-resourced regulatory systems.

One of the key targets is for domestic products to meet 80% of demand and account for 70% of market value (compared to 44% in Q4 2023, according to IQVIA statistics). Additionally, Vietnam aims for 20% of its pharmaceutical manufacturers to meet EU-GMP, PIC-GMP, or equivalent standards by 2030, up from 8.6% (18 out of 210 manufacturers) in January 2025 (Source: DAV/ EudraGMP).

As a pharmaceutical and biotechnological European company, Adamed Pharma (of which Davipharm is a member) leveraging its successful track record in Poland, invests in enhancing product quality in Vietnam to supply local market and boost exports. The official meeting with the Prime Minister Phạm Minh Chính during his visit to Poland underscores Adamed and Davipharm’s commitment to supporting Vietnam’s long-term pharmaceutical industry goals.

Driving Growth with Strong International Partnerships

The Prime Minister Phạm Minh Chính along with Ministers of Health, Planning and Investment, and Industry & Trade met with representatives of Adamed Pharma, including Małgorzata Adamkiewicz, MD, PhD, President of the Supervisory Board and Co-owner, and Michal Wieczorek, General Director at Davipharm. The Prime Minister recognized Adamed’s significant investment and contributions to Vietnam’s pharmaceutical sector and encouraged the company to continue producing affordable, high-quality medicines for Vietnamese people while expanding exports to regional and global markets. He reaffirmed the Vietnamese government’s commitment to supporting Adamed Group’s sustainable growth in the country.

Photo: Prime Minister Phạm Minh Chính and key Vietnamese ministers meet Adamed Group in Warsaw in January 2025

Discussions centered on creating a modern pharmaceutical ecosystem and Davipharm’s key role in connecting Polish expertise with Vietnam’s growing pharmaceutical market. Additionally, the proposal to establish a dedicated working group was explored, aimed at providing strategic insights and advisory support to facilitate the effective implementation of Vietnam’s pharmaceutical development strategy. This initiative would serve as a platform for collaboration between industry stakeholders and policymakers, fostering an open exchange of expertise in alignment with national objectives.

Leading the Way: Davipharm’s 2033 Vision

Davipharm aims to become Vietnam’s number-one pharmaceutical exporter by 2033. The company is committed to producing the high-quality medicines, backed by EU-GMP certification and scientific research. Its goal is to become the leading pharmaceutical exporter, beginning with Southeast Asia and gradually expanding into Europe and beyond.

Davipharm’s strategic initiatives for 2025-2028 focus on multiple areas. The company is establishing itself as a Southeast Asia export hub by registering in ASEAN countries, implementing license-out sales worldwide, and contributing to Vietnam’s economy by improving the trade balance. It is also expanding its factory with a new warehouse, a new production plant, and a quality control laboratory to support its growing operations. Additionally, Davipharm is advancing high-tech production and export by developing pharmaceutical technologies that meet the strict regulatory standards of international markets.

Photo: Davipharm’s storage capacity will have to expand to support ambitious production plans.

By 2028, Davipharm aims to solidify its position as Vietnam’s leading pharmaceutical manufacturer and top exporter. The company will continue investing in infrastructure to increase production and storage capacity. It plans to develop 12 new SKUs annually for international markets, ensuring a consistent pipeline of innovative pharmaceutical products. Davipharm is also committed to introducing value-added medicines that improve healthcare outcomes for Vietnamese patients. To support innovation and talent development, it is strengthening partnerships with universities. Additionally, the company is implementing ESG standards, reinforcing its commitment to sustainability and securing its role as a reliable and desired partner in the global pharmaceutical supply chain.

Strengthening Global Pharmaceutical Standards

In 2024, Davipharm became the first company in Vietnam and Southeast Asia to receive EU-GMP certification for its High Potent (HP) Zone, a high-standard facility specializing in oncology drug production.

Photo: Inside of Davipharm’s HP Zone.

At the start of 2025, the FDA of the Philippines re-certified Davipharm as a GMP manufacturer, granting the company a Certificate of GMP Compliance, covering both High Potent (HP) and non-HP Zones. This achievement further reinforces Davipharm’s commitment to international quality standards and opens new opportunities for global market expansion.

With a vision to deliver high-quality products and services at affordable prices, Davipharm is dedicated to elevating the image of “Made in Vietnam” medicines and supplying products to both local and international markets. Backed by Adamed Pharma, Vietnam’s government, and strong collaborations with academic and regulatory bodies, the company remains steadfast in supporting the long-term pharmaceutical strategy of the country and reshaping the pharmaceutical landscape in Southeast Asia, and beyond.

Photo credits: Vietnam Government Portal, Vietnam News Agency, PAIH

Source: VTV.vn